Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.

Wu JJ, Veverka KA, Lu M, Armstrong AW.

J Dermatolog Treat. 2019 Aug;30(5):454-460. doi: 10.1080/09546634.2018.1535689. Epub 2019 Jan 10.

PMID:
30307343
2.

Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).

Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L.

J Drugs Dermatol. 2015 Dec;14(12):1468-77.

PMID:
26659941
3.

Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.

Griffiths CE, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, Paul C.

Eur J Dermatol. 2018 Jun 1;28(3):356-363. doi: 10.1684/ejd.2018.3302.

PMID:
29952297
4.

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.

Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J.

J Dermatolog Treat. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7.

6.
7.

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.

Gorelick J, Cantrell W, Kucera K, Veverka KA, Gooding K.

J Drugs Dermatol. 2018 Aug 1;17(8):880-884.

PMID:
30124727
8.

Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.

Menter A, Gold LS, Koo J, Villumsen J, Rosén M, Lebwohl M.

Skinmed. 2017 Apr 1;15(2):119-124. eCollection 2017. Review.

PMID:
28528605
10.

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.

Paul C, Leonardi C, Menter A, Reich K, Gold LS, Warren RB, Møller A, Lebwohl M.

Am J Clin Dermatol. 2017 Jun;18(3):405-411. doi: 10.1007/s40257-017-0258-0. Erratum in: Am J Clin Dermatol. 2017 May 24;:.

11.

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.

Queille-Roussel C, Rosen M, Clonier F, Nørremark K, Lacour JP.

Clin Drug Investig. 2017 Apr;37(4):355-361. doi: 10.1007/s40261-016-0489-5.

12.

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.

Jalili A, Lebwohl M, Stein Gold L, Andersen SB, Jensen KL, Pink AE, Segaert S, Berg P, Calzavara-Pinton PG, de la Cueva Dobao P, Thaçi D.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):709-717. doi: 10.1111/jdv.15393.

PMID:
30520168
13.

Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?

Giovene GL, Giacomelli L; AIDA (Italian Association of Outpatient Dermatologists) Working Group.

G Ital Dermatol Venereol. 2018 Dec;153(6):872-876. doi: 10.23736/S0392-0488.18.06143-6. Epub 2018 Sep 27. Review.

14.

Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.

Queille-Roussel C, Olesen M, Villumsen J, Lacour JP.

Clin Drug Investig. 2015 Apr;35(4):239-45. doi: 10.1007/s40261-015-0269-7.

15.

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.

Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, Griffiths CE.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):119-126. doi: 10.1111/jdv.13859. Epub 2016 Aug 17.

16.

A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.

Duvetorp A, Levin LÅ, Engerstedt Mattsson E, Ryttig L.

Acta Derm Venereol. 2019 Apr 1;99(4):393-399. doi: 10.2340/00015555-3112.

17.

Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.

McCormack PL.

Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Review.

PMID:
21967117
18.

Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.

Kim ES, Frampton JE.

Drugs. 2016 Oct;76(15):1485-1492. Review.

PMID:
27663245
19.

Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.

Asche CV, Kim M, Feldman SR, Zografos P, Lu M.

J Med Econ. 2017 Sep;20(9):1000-1006. doi: 10.1080/13696998.2017.1339279. Epub 2017 Jun 19.

PMID:
28581873

Supplemental Content

Support Center